{"groups":[{"description":"This was a multicenter, non-randomized, open-label, uncontrolled, single-arm treatment study of lenalidomide as monotherapy or in combination with dexamethasone in subjects with previously treated relapsed or refractory multiple myeloma, with measurable myeloma paraprotein in serum and/or urine. Subjects who met all of the eligibility criteria were enrolled into the study. Screening procedures took place within 28 days of first dose. Subjects who qualified for participation received oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days.","id":"FG000","title":"Lenalidomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"294"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"478"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"83"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"94"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"960"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1913"}],"type":"STARTED"},{"achievements":[{"comment":"Subjects participated in study until they presented with reason for discontinuation.","groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1913"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}